ClearPoint Neuro (CLPT) to Release Quarterly Earnings on Wednesday

ClearPoint Neuro (NASDAQ:CLPT) is anticipated to release its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect ClearPoint Neuro to post earnings of ($0.25) per share and revenue of $12.00 million for the quarter. Interested persons may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

ClearPoint Neuro (NASDAQ:CLPT) last released its earnings results on Tuesday, March 17th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.05). The firm had revenue of $10.41 million during the quarter, compared to analyst estimates of $10.40 million. ClearPoint Neuro had a negative net margin of 69.08% and a negative return on equity of 122.17%. On average, analysts expect ClearPoint Neuro to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ClearPoint Neuro Stock Performance

NASDAQ CLPT opened at $11.10 on Wednesday. The company has a market cap of $332.89 million, a P/E ratio of -12.20 and a beta of 1.29. The company has a debt-to-equity ratio of 1.75, a current ratio of 5.91 and a quick ratio of 5.13. The stock has a 50-day moving average of $10.53 and a two-hundred day moving average of $13.92. ClearPoint Neuro has a 1-year low of $8.27 and a 1-year high of $30.10.

Institutional Trading of ClearPoint Neuro

Several hedge funds have recently modified their holdings of the stock. Commonwealth Equity Services LLC raised its stake in shares of ClearPoint Neuro by 1.7% in the fourth quarter. Commonwealth Equity Services LLC now owns 65,557 shares of the company’s stock valued at $897,000 after acquiring an additional 1,109 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of ClearPoint Neuro by 4.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 26,791 shares of the company’s stock valued at $367,000 after acquiring an additional 1,204 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of ClearPoint Neuro in the fourth quarter valued at $25,000. BNP Paribas Financial Markets raised its stake in shares of ClearPoint Neuro by 2,435.2% in the second quarter. BNP Paribas Financial Markets now owns 2,231 shares of the company’s stock valued at $27,000 after acquiring an additional 2,143 shares in the last quarter. Finally, Russell Investments Group Ltd. raised its stake in ClearPoint Neuro by 1,079.0% in the third quarter. Russell Investments Group Ltd. now owns 2,358 shares of the company’s stock valued at $51,000 after buying an additional 2,158 shares in the last quarter. 30.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on CLPT. B. Riley Financial lifted their target price on ClearPoint Neuro from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Monday, April 20th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $14.50.

About ClearPoint Neuro

ClearPoint Neuro, Inc is a medical technology company specializing in the development and commercialization of an MRI-guided therapy platform for minimally invasive neurosurgical procedures. Headquartered in Cambridge, Massachusetts, the company’s flagship ClearPoint® SmartFrame™ system enables surgeons to perform accurate and efficient intracranial interventions by providing real-time magnetic resonance imaging feedback. This technology is designed to improve patient safety and outcomes in treatments ranging from deep brain stimulation electrode placement to laser ablation of epileptic foci and brain tumors.

The ClearPoint System integrates hardware, software and imaging capabilities to guide instruments through the brain with submillimeter precision.